Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) has provided an announcement.
Qiagen has reported a managers’ transaction under EU market abuse regulations involving Metin Colpan, a member of its administrative or supervisory body. The disclosure covers the vesting and net share settlement of restricted stock units originally granted in 2021, resulting in the delivery of common shares outside a trading venue.
The transaction involved the release of 4,490 restricted stock units with a zero exercise price and subsequent receipt of 2,253 common shares after withholding a portion to cover taxes and related costs based on the share price at vesting. This filing underscores Qiagen’s adherence to transparency rules on insider-related equity awards, providing investors with visibility into management’s share-based compensation activity.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a life sciences company based in Venlo, Netherlands, whose shares are listed on multiple European exchanges as well as the NYSE and Swiss markets. It develops and sells sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical development, serving laboratories and healthcare stakeholders worldwide.
Average Trading Volume: 2,173,009
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.1B
See more data about QGEN stock on TipRanks’ Stock Analysis page.